PsyBio Therapeutics Corp. (PSYBF)
USD 0.0
(-98.0%)
USD 0.0
(-98.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 1.98 Million USD | 53.53% |
| 2021 | 1.29 Million USD | 26.1% |
| 2020 | 1.02 Million USD | 2948.58% |
| 2019 | 33.57 Thousand USD | -22.47% |
| 2018 | 43.3 Thousand USD | 19.9% |
| 2017 | 36.11 Thousand USD | -62.66% |
| 2016 | 96.71 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 1.95 Million USD | -1.22% |
| 2023 Q2 | 1.97 Million USD | 0.7% |
| 2022 Q2 | 1.26 Million USD | -12.33% |
| 2022 Q1 | 1.44 Million USD | 11.71% |
| 2022 FY | 1.98 Million USD | 53.53% |
| 2022 Q3 | 1.31 Million USD | 4.01% |
| 2022 Q4 | 1.98 Million USD | 50.72% |
| 2021 Q3 | 1.69 Million CAD | -0.49% |
| 2021 FY | 1.29 Million USD | 26.1% |
| 2021 Q4 | 1.29 Million USD | -24.08% |
| 2021 Q1 | 1.18 Million CAD | 1176.33% |
| 2021 Q2 | 1.7 Million CAD | 44.59% |
| 2020 Q2 | 33.57 Thousand USD | 0.86% |
| 2020 Q1 | 33.28 Thousand USD | 0.0% |
| 2020 FY | 1.02 Million USD | 2948.58% |
| 2020 Q4 | 92.56 Thousand CAD | 0.0% |
| 2019 FY | 33.57 Thousand USD | -22.47% |
| 2018 FY | 43.3 Thousand USD | 19.9% |
| 2017 FY | 36.11 Thousand USD | -62.66% |
| 2016 FY | 96.71 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7122.353% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 79.069% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.266% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -144.971% |
| Rebus Holdings, Inc. | 5.24 Million USD | 62.203% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.643% |
| Qrons Inc. | 1.48 Million USD | -33.089% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -61.579% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.355% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4332.853% |
| Skye Bioscience, Inc. | 14.07 Million USD | 85.92% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.283% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 79.323% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -369.985% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.04% |
| Intellipharmaceutics International Inc. | 12 Million USD | 83.501% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 48.556% |
| Mesoblast Limited | 188.44 Million USD | 98.949% |
| Marizyme, Inc. | 26.67 Million USD | 92.573% |
| Genus plc | 485 Million USD | 99.591% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 66.089% |
| Pharming Group N.V. | 244.07 Million USD | 99.188% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 1.434% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 21.262% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 47.86% |
| ContraFect Corporation | 32.53 Million USD | 93.909% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 48.237% |
| IMV Inc. | 37.93 Million USD | 94.777% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 83.178% |
| MultiCell Technologies, Inc. | 1617.67 USD | -122379.121% |
| ONE Bio Corp. | 27.49 Million USD | 92.794% |
| Accustem Sciences Inc. | 1.07 Million USD | -83.584% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.441% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 6.324% |
| Q BioMed Inc. | 8.13 Million USD | 75.638% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.611% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 61.498% |
| Biomind Labs Inc. | 1.49 Million USD | -32.21% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.331% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 78.088% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 89.234% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -38.18% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1294.354% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -885.157% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 65.517% |
| GB Sciences, Inc. | 5.41 Million USD | 63.428% |
| Alpha Cognition Inc. | 7.16 Million USD | 72.347% |
| HST Global, Inc. | 593.59 Thousand USD | -233.782% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -57.347% |
| Halberd Corporation | 728.71 Thousand USD | -171.889% |
| Enzolytics Inc. | 365.26 Million USD | 99.458% |
| Agentix Corp. | 2.51 Million USD | 21.081% |
| Resverlogix Corp. | 67.39 Million USD | 97.06% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -136.227% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.555% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -15.596% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.993% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 83.355% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 45.942% |
| AVAX Technologies, Inc. | 3.99 Million USD | 50.39% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7086.724% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.851% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -730.201% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 46.943% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -191.012% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 26.933% |
| Kadimastem Ltd | 3.5 Million USD | 43.47% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2860.313% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.058% |
| BioStem Technologies, Inc. | 15.9 Million USD | 87.543% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -326.364% |
| LadRx Corporation | 2.2 Million USD | 9.962% |
| Cell Source, Inc. | 15.8 Million USD | 87.465% |
| Regen BioPharma, Inc. | 5.45 Million USD | 63.696% |
| Regen BioPharma, Inc. | 5.45 Million USD | 63.696% |
| NovAccess Global Inc. | 7.86 Million USD | 74.795% |
| Affymax, Inc. | 8.87 Million USD | 77.665% |
| Itoco Inc. | 1.65 Million USD | -19.85% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 3.425% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 67.246% |
| Mobile Lads Corp. | 1.31 Million USD | -50.842% |
| CytoDyn Inc. | 127.89 Million USD | 98.451% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4640.085% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -26.49% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 82.062% |
| SYBLEU INC | 681.41 Thousand USD | -190.765% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 67.53% |
| International Stem Cell Corporation | 5.27 Million USD | 62.454% |
| Bioxytran, Inc. | 3.24 Million USD | 39.027% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -216.599% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 57.088% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.167% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 91.101% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 2.176% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 63.832% |
| Neutra Corp. | 973.52 Thousand USD | -103.518% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 93.171% |
| PureTech Health plc | 125.58 Million USD | 98.422% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 47.265% |
| IXICO plc | 1.9 Million USD | -4.263% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 90.349% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.082% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Cellectis S.A. | 249.36 Million USD | 99.205% |